NeuroPace price target raised to $19 from $18 at Cantor Fitzgerald

Cantor Fitzgerald analyst Ross Osborn raised the firm’s price target on NeuroPace (NPCE) to $19 from $18 and keeps an Overweight rating on the shares. At the company’s Investor Day, management discussed new data on Responsive Neurostimulation Device, upgrades to the system’s software and hardware, and a path to indications that are expected to double the company’s addressable market opportunity, the analyst tells investors in a research note. The firm continues to believe NeuroPace is undervalued and that the company will exceed expectations.